Hosted on MSN23h
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...
Science Daily19h
Mouse study finds impaired cell development: Intermittent fasting could be unsafe for teenagers
A recent study reveals that age plays a significant role in the outcomes of intermittent fasting. Researchers discovered that chronic intermittent fasting disrupted the development of ...